Strategic Framework · Clinical Evidence
From Symptom to Cure
Snore.com captures patients at the earliest point of clinical awareness — a single search word — and routes them through diagnosis, risk stratification, and treatment across seven high-value snoring cohorts.
Own the Symptom → Guide to Your Cure
Step 1
Symptom Capture
User types “snoring” — snore.com is the AI-surfaced, semantically authoritative destination
~1 billion habitual snorers worldwide · 40% M / 20% F adult population prevalence
Step 2
Risk Awareness
BMI framing, partner sleep disruption, cardiometabolic co-morbidity and sleep apnea education — unbranded & clinician-reviewed
Unbranded disease education · no Rx messaging required
Step 3
Cohort Identification
OSA · T2DM · Hypertension · Cardiovascular · MASLD/NAFLD · CKD · Overweight
7 high-value clinical pathways · evidence-based routing
Step 4
Clinical Triage
Physician workflow tools · sleep study routing · telehealth linkage · wearables and nearables connections · HCP education assets
HCP workflow support · reduces clinician burden
Step 5
Therapeutic Pathways
CPAP · weight management · GLP-1 / incretin Rx · pharmacy dispensing & adherence support · neurostimulators · oral appliances · smart beds
Pharma & device Rx · ~$60B GLP-1 market
Step 6
Patient Treatment Selection
Participation of treatment-specific medical professionals.
Prescription drugs and devices · Lifestyle Risk factors · medical follow up
Step 7
Cure / Outcome
Diagnosed · treated · adherent · quality of life restored
Patient success · measurable health outcome
Published Sources
Clinical Evidence Summary
| Cohort | Key Statistic | Strategic Significance |
|---|---|---|
| OSA / Obesity | 936M adults with OSA globally; 80%+ undiagnosed (Benjafield et al., PubMed); 95% of OSA patients are habitual snorers (Platon et al., PMC) | Top-of-funnel GLP-1 opportunity; semaglutide now FDA-labelled for OSA |
| Overweight snorers | 40% M / 20% F habitual snoring (Levartovsky et al., PMC); 50%partner sleep disrupted nightly (Ye et al., PMC review) | Consumer urgency cohort; high search volume driver for snore.com |
| Type 2 Diabetes | 60.3% T2DM patients snored (Ozol et al., PubMed); Increasing evidence snoring alone is a strong predictor of T2DM (Muraki et al., PMC) | Direct incretin bridge — links snoring complaint to metabolic Rx conversation |
| Hypertension | Regular snoring associated with elevated BP independent of OSA (Lechat et al., PMC) | Antihypertensive + weight management crossover |
| Cardiovascular | +28% CAD increased risk; Up to +46% increased stroke risk in snorers (Liu et al.; Bai et al., PubMed) | Prevention narrative; strong case for cardiometabolic unbranded campaign |
| MASLD / NAFLD | Habitual snoring independently associated with higher NAFLD prevalence (Wang et al., PMC) | Extends domain into hepatometabolic disease and the full obesity pharmacotherapy funnel |
| CKD | 57% OSA prevalence in CKD; obesity a classic linked risk factor (Pisano et al., PMC); Snoring frequency independently associated with CKD prevalence (jiang et al., PubMed) | Convergence of SGLT2 and GLP‑1 science in the treatment of cardiovascular and renal disease. |
Asset Acquisition
Ready to own the world’s most authoritative snoring domain?
Snore.com has been solely owned by Dr. Murray Moffat since 1995 — a 30-year trust signal no new domain can replicate. Now available for purchase. All transaction enquiries through Hilco Digital Assets.
Provenance & Medical Information
Dr. Murray Moffat
Retired Sleep Physician · Medical Consultant, MySleepAI
[email protected]